Advertisement

Drugs in R & D

, Volume 1, Issue 4, pp 317–318 | Cite as

Landiolol

ONO 1011
Section 1: Antiarrhythmic Agent Adis R&D Profile
  • 4 Downloads

Keywords

Atrial Fibrillation Adis International Limited Atrial Flutter Esmolol Landiolol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Atarashi H, Kuruma A, Ino T, et al. ONO-1101: a new ultrashort acting beta-adrenergic blocker: initial study of efficacy, safety and pharmacokinetics. Cardiovasc Drugs Ther 1993; 7 Suppl. 2: 444Google Scholar
  2. 2.
    Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull 1992; 40: 1462–9PubMedCrossRefGoogle Scholar
  3. 3.
    Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4949–78Google Scholar
  4. 4.
    Kato K, Iinuma H, Hayakawa H, et al. Clinical effect of intravenous infusion of landiolol hydrochloride (ONO-1101) on paroxysmal atrial fibrillation and atrial flutter: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4903–24Google Scholar

Copyright information

© Adis International Limited 1999

Personalised recommendations